Genetic susceptibility to immune-related adverse events among melanoma patients treated with ipilimumab.

被引：0
|
作者：
Pluta, John [1 ]
Qian, Lu [2 ]
D'Andrea, Kurt [1 ]
Duan, Chunzhe [3 ]
Weathers, Benita [1 ]
Wind-Rotolo, Megan [4 ]
Kanetsky, Peter [5 ]
Nathanson, Katherine [1 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA
[3] Roche Holding AG, Shanghai, Peoples R China
[4] Bristol Myers Squib, New York, NY USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1352
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy
    Albarran-Artahona, Victor
    Laguna, Juan-Carlos
    Gorria, Teresa
    Torres-Jimenez, Javier
    Pascal, Mariona
    Mezquita, Laura
    DIAGNOSTICS, 2022, 12 (09)
  • [32] Ipilimumab/nivolumabRheumatological immune-related adverse events: 2 case reports
    Reactions Weekly, 2020, 1831 (1) : 171 - 171
  • [33] Correlation of immune-related adverse events with peripheral baseline immune markers and overall survival in patients with metastatic melanoma on ipilimumab and chemotherapy.
    Esfahani, Khashayar
    Thebault, Pamela
    Lapointe, Rejean
    Jamal, Rahima
    Miller, Wilson H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [34] Radiologic Aspects of Immune-Related Tumor Response Criteria and Patterns of Immune-Related Adverse Events in Patients Undergoing Ipilimumab Therapy
    O'Regan, Kevin N.
    Jagannathan, Jyothipriya P.
    Ramaiya, Nikhil
    Hodi, F. Stephen
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2011, 197 (02) : W241 - W246
  • [35] TREATMENT GUIDELINES FOR THE MANAGEMENT OF IMMUNE-RELATED ADVERSE EVENTS IN PATIENTS TREATED WITH IPILIMUMAB, AN ANTI-CTLA4 THERAPY
    Chin, K.
    Ibrahim, R.
    Berman, D.
    Yellin, M.
    Lowy, I.
    Lin, R.
    Hoos, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 244 - 245
  • [36] AUTOANTIBODY PROFILING IN PROSTVAC AND IPILIMUMAB TREATED PROSTATE CANCER PATIENTS REVEALS POTENTIAL BIOMARKERS OF IMMUNE-RELATED ADVERSE EVENTS
    Budde, P.
    Marte, J. L.
    Zucht, H. -D.
    Bhandari, S.
    Tuschen, M.
    Schulz-Knappe, P.
    Madan, R. A.
    Gulley, J. L.
    Schlom, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 247 - 247
  • [37] Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults
    Schonfeld, Sara J.
    Tucker, Margaret A.
    Engels, Eric A.
    Dores, Graca M.
    Sampson, Joshua N.
    Shiels, Meredith S.
    Chanock, Stephen J.
    Morton, Lindsay M.
    JAMA NETWORK OPEN, 2022, 5 (03)
  • [38] Autoantibody Profiling in Prostvac and Ipilimumab Treated Prostate Cancer Patients Reveals Potential Biomarkers of Immune-Related Adverse Events
    Budde, Petra
    Marte, Jennifer
    Zucht, Hans-Dieter
    Bhandari, Saurabh
    Tuschen, Manuel
    Schulz-Knappe, Peter
    Gulley, James
    Heery, Christopher
    Madan, Ravi
    Schlom, Jeffrey
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [39] Association between immune-related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis
    Euvrard, Romain
    Robert, Marie
    Mainbourg, Sabine
    Dalle, Stephane
    Lega, Jean-Christophe
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2024, 38 (02) : 369 - 379
  • [40] Immune-Related Adverse Events Involving Multiple Organ Sites in a Patient Treated With Nivolumab Plus Ipilimumab
    Remolina-Bonilla, Yuly A.
    Jimenez-Franco, Brenda
    Lam, Elaine T.
    Bourlon, Maria T.
    ONCOLOGY-NEW YORK, 2020, 34 (05): : 171 - 174
12345